Medical devices, due to their direct or indirect effects on the human body and help with disease treatment and diagnosis, their quality directly determines the diagnosis and treatment effect. Therefore, medical devices are constantly being updated and upgraded to improve the quality of core technologies and strive to provide better health services. .

In the past, China’s medical device market, especially the high-end medical market, was mostly monopolized by foreign giants, which greatly increased medical costs. Today, when domestic brands break through technical barriers and gradually rise, domestic medical devices have also been on the stage of high-end products，with the support of the country’s procurement policy and technological innovation encouragement policy, domestic medical devices have begun to gradually replace imported products, escorting the health of the people of the motherland，however, in the eyes of many medical workers and even the public, the quality and technology of domestic medical devices are still untrustworthy. In the face of this situation, what should domestic brands start from? After entering the high-end market, can they increase public awareness?

At present, the domestic mid-to-high-end medical device market is still dominated by large-scale international medical device manufacturers, but leading domestic medical device companies with their own intellectual property rights have formed a competitive trend with them in this market and occupy a considerable market share, and The market share of this part of the manufacturers is constantly expanding. In the mid-to-high-end medical device market,core technology and product quality assurance are always the key to competition，as product competition becomes increasingly fierce, companies that have advanced technology and can manufacture independently can ensure product quality and cost control to produce products that are more suitable for Chinese medical use, and are more likely to gain the upper hand in the market.

Taking in vitro diagnostic reagents as an example, immunodiagnosis accounts for 1/3 of all in vitro diagnostics market. The screening of specific antibodies and the processing of carrier materials have become the core technology of immunodiagnosis.In recent years, the continuous optimization of antibodies and the iterative update of new materials have brought brand-new development to the immunodiagnostic industry.However, for the latest projects, many companies still use imported antibodies to complete subsequent processing, and it is difficult to independently control the screening and production of antibodies, which directly causes the problems of high cost and difficult quality control. How to master the core technology and self-manufacturing has become a major indicator for evaluating the strength of diagnostic reagent companies.

With the gradual upgrade of medical equipment, the requirements for doctors are getting higher and higher, and many new technologies and products need to be retrained for doctors. Under the advantage of leading technology, foreign giants have a firm grasp of continuing education resources for doctors. Doctors can have more access to products and naturally have a deeper understanding of the performance and operation of enterprise products. The re-education of domestic clinicians Compared with foreign giants, there is still a certain gap, which is also a major reason why domestic medical practitioners have limited awareness of domestic medical devices.

In particular, as domestic companies’ technology products are gradually entering the mid-to-high-end market, domestic brands need to increase their sense of social responsibility, actively invest in funds, and participate in the continuing education of relevant medical device doctors, so that clinicians can have more exposure to domestic products. It is best to form interactive feedback with domestic brands, build a virtuous circle of production, education, research and medical research, and create domestic brands that are suitable for Chinese doctors.

Today, when industry cooperation is increasing, the medical industry has also carried out extensive "cross-border cooperation" with other industries such as artificial intelligence and the Internet to provide more convenient and efficient services for clinics. New concepts such as cloud medical care and smart medical care are emerging in an endless stream. It is also a great opportunity for domestic medical devices to show their strength and quality. Of course, this requires an earlier strategic layout and higher strategic investment by medical device manufacturers.

For example, the current domestic active promotion of hierarchical diagnosis and treatment policies, the demand for "telemedicine" and "medical consortium" has emerged, and the combination of domestic medical equipment and the Internet, especially the hottest "5G" technology, is even more critical.

Ningbo Aocheng Biotechnology Co., Ltd. is a high-tech biological enterprise focusing on the early detection, diagnosis, prevention and monitoring of diseases. By providing reliable, fast and convenient in vitro diagnostic products, it can provide accurate test results for diagnosis and treatment.

Aocheng has multi-platform independent research and development capabilities for immunodiagnosis, combined with genetic engineering and hybridoma antibody research and development, and continues to conduct in-depth exploration and prospective research in the field of high-risk diseases of pregnant women such as hypertension. We will be committed to providing professional maternal and child health Clinical diagnostic solutions. In the future, we will mainly use advanced technologies such as artificial intelligence, medical big data, and "5G" to add value to the current diagnostic platform to create value for medical institutions and patients.